Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

Shares of First Wave BioPharma were halted due to a circuit breaker after experiencing a significant increase of 45.8%.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:36 pm

Trinity Place Holdings Inc. (TPHS) shares surged 80.1% in pre-market trading to $0.2056 after the company announced a mortgage loan forbearance extension to January 31, 2024. Other stocks also showed significant movement in pre-market trading, with Sigma Additive Solutions, Inc. (SASI) and Carbon Revolution Public Limited Company (CREV) among the top gainers. Conversely, Addentax Group Corp. (ATXG) and Calidi Biotherapeutics, Inc. (CLDI) were among the top losers.

Portfolio Pulse from Avi Kapoor

January 03, 2024 | 12:59 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. First Wave BioPharma (FWBI) saw a notable increase of 40.8%, while Strata Skin Sciences (SSKN) led the decliners with a 12.6% drop. Other gainers included Bone Biologics (BBLG), Biolase (BIOL), Qilian Intl Hldg Gr (QLI), Agile Therapeutics (AGRX), and Bullfrog AI Hldgs (BFRG). Losers comprised Sientra (SIEN), Ocugen (OCGN), ENDRA Life Sciences (NDRA), Onconetix (ONCO), and SCYNEXIS (SCYX). Market caps varied, with Ocugen having the highest at $159.0 million.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:31 pm

First Wave BioPharma's stock price has increased following an updated price target from Roth MKM, which raised its PT to $40.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 9:15 pm

DouYu International Holdings Limited (NASDAQ:DOYU) announced a share repurchase program of up to $20 million of ordinary shares in the form of ADSS, causing its shares to rise by 14.2% to $0.8320. Other stocks experienced significant movements in Thursday's mid-day session, with various companies seeing substantial gains and losses for diverse reasons, including FDA guidance, analyst ratings, public offerings, and patent lawsuit outcomes.

Portfolio Pulse from Avi Kapoor

December 28, 2023 | 6:07 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Cingulate (CING) saw the largest increase, with shares up 188.5% to $11.51. SenesTech (SNES) and Palisade Bio (PALI) also saw substantial gains of 82.02% and 55.83%, respectively. On the losing side, Bluejay Diagnostics (BJDX) experienced the largest drop, falling 34.5% to $1.15. Other notable decliners include CytoSorbents (CTSO) and First Wave BioPharma (FWBI), with decreases of 32.52% and 15.74%, respectively.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 1:07 pm

U.S. stocks traded mixed with the Dow slightly up and the S&P 500 and Nasdaq Composite slightly down. Crude oil prices fell by 1.4%, while gold and silver prices rose. First Wave BioPharma's stock spiked after announcing a potential sale of its Niclosamide program. Cytokinetics surged following positive trial results, and Coherus BioSciences gained on FDA approval news. Conversely, Hallmark Financial Services, Bluejay Diagnostics, and Iovance Biotherapeutics saw significant stock declines due to various company-specific news.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 7:19 pm

Reneo Pharmaceuticals, Inc. (RPHM) shares rose by 13.6% to $1.59 after receiving an acquisition proposal from Concentra for $1.80 per share. Other stocks also showed significant movement in Wednesday's mid-day session, with notable gainers including First Wave BioPharma, Inc. (FWBI), Cingulate Inc. (CING), and Cytokinetics, Incorporated (CYTK), among others. Losers for the day included Hallmark Financial Services, Inc. (HALL), Baosheng Media Group Holdings Limited (BAOS), and Iovance Biotherapeutics, Inc. (IOVA).

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 7:11 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Cytokinetics (CYTK) led the gainers with a 73.6% increase, while IMAC Holdings (BACK) led the losers with a 25% decrease. Other notable movers included Cingulate (CING), First Wave BioPharma (FWBI), Palatin Techs (PTN), Coherus BioSciences (CHRS), and Bone Biologics (BBLG) on the gainers' side, and Bluejay Diagnostics (BJDX), Iovance Biotherapeutics (IOVA), Atreca (BCEL), SCWorx (WORX), and Novo Integrated Sciences (NVOS) among the losers.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 5:31 pm

U.S. stocks traded higher, with the Dow Jones gaining around 80 points. Consumer discretionary shares led gains, while information technology shares fell. The Richmond Fed Manufacturing Index dropped to -11, the lowest in ten months. First Wave BioPharma, Cytokinetics, and Coherus BioSciences saw significant stock increases due to positive developments. Hallmark Financial Services announced its intention to delist from Nasdaq, Bluejay Diagnostics initiated a clinical study, and Iovance Biotherapeutics faced an FDA clinical hold, all leading to stock declines. Gold rose 1%, and oil prices fell slightly.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 5:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.